A Phase 1 Single-Dose, Dose Escalation Study to Evaluate the Safety and Tolerability of LY3114062 in Subjects With Inflammatory Arthritis
Phase of Trial: Phase I
Latest Information Update: 20 Jul 2015
At a glance
- Drugs LY 3114062 (Primary) ; LY 3114062 (Primary)
- Indications Arthritis
- Focus Adverse reactions
- Sponsors Eli Lilly
- 16 Jul 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 16 Jul 2014 Planned End Date changed from 1 Sep 2015 to 1 Aug 2015 as reported by ClinicalTrials.gov record.
- 16 Jul 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.